TK-6302

N/A

Report date: 2025/12/10 17:16:58

Base Information

Drug NameTK-6302
Drug Alias NameTK-6302
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsMelanoma antigen preferentially expressed in tumors modulators
TargetsMelanoma antigen preferentially expressed in tumors
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesT-knife Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesT-knife Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A